# Primary neuroendocrine carcinoma of the fallopian tube with exceeding 10 years follow-up: Case report and review of the literature

**Authors:** Jun Ma, Yujing Tang, Wei He, Jun Shi

PMC · DOI: 10.1016/j.gore.2025.101692 · Gynecologic Oncology Reports · 2025-02-11

## TL;DR

A rare case of fallopian tube neuroendocrine carcinoma is reported with over 10 years of survival following surgery and chemotherapy.

## Contribution

This case presents the longest survival reported for fallopian tube neuroendocrine tumors and highlights a potential treatment approach.

## Key findings

- The patient survived over 10 years after treatment for fallopian tube neuroendocrine carcinoma.
- Surgery and EP chemotherapy (cisplatin and etoposide) were effective in this case.
- This case provides evidence for a potential standardized treatment approach for this rare condition.

## Abstract

•Neuroendocrine carcinoma of the fallopian tube is very rare.•We present a neuroendocrine carcinoma of the fallopian tubes that have survived for over 10 years.•We emphasized the effectiveness of surgery and EP chemotherapy for neuroendocrine carcinoma of the fallopian tubes.

Neuroendocrine carcinoma of the fallopian tube is very rare.

We present a neuroendocrine carcinoma of the fallopian tubes that have survived for over 10 years.

We emphasized the effectiveness of surgery and EP chemotherapy for neuroendocrine carcinoma of the fallopian tubes.

Neuroendocrine carcinomas typically originate from the digestive system and lungs; however, their occurrence in the female genital tract, particularly in the fallopian tube, is exceedingly rare. Currently, there is no established treatment guideline for neuroendocrine neoplasms of the fallopian tube. In this report, we presented a case of small cell neuroendocrine carcinoma of the fallopian tube, with a survival period exceeding 10 years—which is the longest recorded survival among reported cases of fallopian tube neuroendocrine tumors. The patient underwent a standard open radical tumor resection and lymphadenectomy, followed by adjuvant chemotherapy with cisplatin and etoposide, offering valuable evidence for potential standardized treatment approaches in such rare case.

## Linked entities

- **Chemicals:** cisplatin (PubChem CID 5460033), etoposide (PubChem CID 36462)
- **Diseases:** neuroendocrine carcinoma (MONDO:0002120)

## Full-text entities

- **Diseases:** Primary neuroendocrine carcinoma of the fallopian tube (MESH:D005185), neuroendocrine neoplasms (MESH:D009369), Neuroendocrine carcinomas (MESH:D018278)
- **Chemicals:** cisplatin (MESH:D002945), etoposide (MESH:D005047)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11872545/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11872545/full.md

## References

14 references — full list in the complete paper: https://tomesphere.com/paper/PMC11872545/full.md

---
Source: https://tomesphere.com/paper/PMC11872545